Olanzapine/samidorphan
Combination drug
From Wikipedia, the free encyclopedia
Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder.[1] It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist.[1][2][3] Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect.[4][5] The formulation was approved for medical use in the United States in May 2021.[1][6]
Trade namesLybalvi
Other namesALKS-3831; OLZ/SAM
| Combination of | |
|---|---|
| Olanzapine | Atypical antipsychotic |
| Samidorphan | Opioid antagonist |
| Clinical data | |
| Trade names | Lybalvi |
| Other names | ALKS-3831; OLZ/SAM |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a621051 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
